Tranzyme refocus failure confirmed as TZP-102 crashes again
Tranzyme Pharma is stopping a second clinical trial with TZP-102, an oral ghrelin agonist, as a treatment for diabetic gastroporesis because it failed to outperform placebo.
Tranzyme Pharma is stopping a second clinical trial with TZP-102, an oral ghrelin agonist, as a treatment for diabetic gastroporesis because it failed to outperform placebo.